Connect with us

COVID19

COVAXIN: Human Trials Of India’s First COVID-19 Vaccine Begin Today At AIIMS, Delhi

Anybody willing to participate in the trial can send an email to [email protected]

Published

on

NEW DELHI: India’s first coronavirus vaccine COVAXIN human trials are beginning today at the All India Institute of Medical Science (AIIMS), Delhi after its Ethics Committee gave its nod.

COVAXIN is an indigenously developed COVID-19 vaccine candidate following which country’s premier hospital is all set to begin the exercise by enrolling healthy volunteers.

The country’s top drug regulator Drug Controller General of India (DCGI) had recently given a green signal for human clinical trials for COVID-19 vaccine candidate Covaxin, which has been developed by the Hyderabad-based Bharat Biotech in collaboration with the ICMR and the National Institute of Virology (NIV).



How to participate in human trials of COVAXIN

Anybody willing to participate in the trial can send an email to [email protected] or an SMS to or call on 7428847499, he said. The institute may also put up these contact details on its website.


The DCGI has permitted two vaccines — one developed by the Bharat Biotech in collaboration with the ICMR and another one by Zydas Cadila Healthcare Ltd to go in for phase I and II human clinical trials.

The two vaccine candidates have undergone successful toxicity studies in rats, mice and rabbits and these data was submitted to DCGI following which both got clearance to start the early phase human trials early this month.


Approximately 1,000 human volunteers would be participating in the exercise for each of the two indigenously developed vaccine candidates, he had said.

The first phase of clinical trials will involve around 300 people, and the subsequent phase will add another 700, according to the earmarked hospitals.

Bharat Biotech produces billions of vaccine doses fighting infections including rotavirus and hepatitis. In 2015, the manufacturer produced the first India-made rotavirus vaccine priced at $1 (€0.89) a dose and now part of the World Health Organization’s immunization program.

Highlights:

  • AIIMS-Delhi is among the 12 sites selected by the Indian Council for Medical Research (ICMR) for conducting phase I and II human trials of Covaxin.
  • In phase I, the vaccine would be tested on 375 volunteers and a maximum of 100 of them would be from AIIMS.
  • Healthy volunteers having no comorbid conditions and without a history of COVID-19, aged more than 18 years and less than 55 years, would be eligible to participate in the randomised, double-blind, placebo-controlled clinical trial.
  • A few volunteers have already registered for the trial. AIIMS will start the screening of the individuals and evaluate their health condition from Monday (today) onwards before vaccinating them.
  • COVID-19 vaccine candidate Covaxin, developed by the Hyderabad-based Bharat Biotech in collaboration with the ICMR and the National Institute of Virology (NIV), had recently got the nod for human clinical trials from the Drugs Controller General of India (DCGI).
  • Noting that this was the first indigenous vaccine being developed by India, ICMR Director-General Dr Balram Bhargava in a letter to principal investigators of the 12 sites recently had asked them to fast-track the human clinical trial approvals stating it is one of the “top priority projects which is being monitored at the top-most level of the government”.
  • The trials have so far started in AIIMS, Patna and some more sites.

Vaccine development takes place in phased clinical trials, each with more test subjects to determine if a vaccine candidate produces the desired antibody response with a correspondingly low level of side effects.

A global race is underway to develop and mass-produce an effective vaccine against SARS-CoV-2.


There are more than 100 vaccine candidates in pre-clinical development by pharmaceutical companies, academic institutions, government agencies, and others.

According to the WHO, as of July 7, there are 17 vaccine candidates undergoing clinical trials in several countries. Although governments are pre-ordering billions of doses of promising candidates, no vaccine is expected to be approved for use over the next several months.

Continue Reading
Comments

COVID19

COVID-19: Clinical Trial Of Ayurvedic Remedy Shows Encouraging Results

Over 85% of patients on the natural protocol tested negative for coronavirus on day 5.

Published

on

MUMBAI (Maharashtra): A groundbreaking interim report on a clinical trial being conducted in three hospitals has shown that Covid-19 patients on natural treatment are resolving most symptoms earlier than those on conventional medicines. The interim report on a combination treatment of an Ayurvedic remedy called ‘Immunofree’ by Corival Life Sciences, and Nutraceutical called ‘Reginmune’ by Biogetica have shown exceptional results as against the present government SOP of conventional medicines for coronavirus treatment.

When compared with conventional treatments for COVID-19, Ayurvedic treatment has shown quicker improvement too. 86.66 per cent of patients undergoing a natural treatment tested negative by the fifth day vs 60 per cent patients on conventional treatment.

On the 10th day, all patients tested negative for the virus after Ayurvedic treatment.

Furthermore, numerous tests such as C reactive protein, Procalcitonin, D Dimer and RT-PCR for novel coronavirus are also showing 20 to 60 per cent better improvement for the natural treatment, when compared to conventional treatment.


Numerous subjective endpoints such as body pain and fatigue are also leaning towards natural treatment. Both Clinician’s Global Assessment of Symptoms and Subject’s Global Assessment of Symptoms clearly showed improvements on both arms showing more significant data in the test group.

The three hospitals where Ayurvedic clinical trials are taking place in India are Government Medical Hospital, Srikakulam Andhra Pradesh; Parul Sevashram Hospital, Vadodara, Gujarat, and Lokmanya Hospital Pune, Maharashtra.

The conventional treatment in use depends on the severity of the patient and includes HCQ, Azithromycin, Favipiravir and Cetirizine. This trial also has broader inclusion criteria than others conducted on natural medicine as it includes patients up to 70 years old, with low oxygen saturation and co-morbidities.


It is significant to note that none of the patients on the natural treatment progressed past moderate, needed ventilators or had any adverse events. These precedent-setting results have led to accelerated enrolment into this trial and statistically significant results should be ready by month-end.

Continue Reading

COVID19

COVID-19: IIT Kharagpur Develops Telemedicine Tech For Corona Homecare

The system is accessible by any standard internet browser and also from a mobile device.

Published

on

KHARAGPUR (West Bengal): Amid the world, and India, struggling with the mayhem caused by COVID-19 pandemic. researchers at IIT Kharagpur’s Department of Computer Science & Engineering have developed a telemedicine system, iMediX.

The system integrates homecare with healthcare services from the hospital. Considering the emergent needs due to the pandemic, the system facilitates critical health care support to the patients at their doorsteps through remote consultation by a physician.

The system is accessible by any standard internet browser and also from a mobile device.

In this system, a patient signs up to get an account by providing his/her Email ID or Mobile number. Then the patient can make a request for consultation by choosing a Department of the hospital, entering the chief complaints and uploading necessary scanned medical records. The hospital administration processes the request and assigns a doctor. The doctor after logging in sets an appointment date and time for the patient and the system communicates the information to the patient by Email and SMS. On the day of the visit, the doctor consults the patient using video conferencing and advises the patient by writing a prescription, which is sent by Email to the patient. The patient can also download the prescription from his or her account.


Prof. Jayanta Mukhopadhyay, the lead researcher in this field remarked, “As the number of cases of home isolation and home quarantine is increasing, the system will cater to the needs of the present situation. It would be useful also to follow up and treat aged patients.”

iMedX is being adopted for public use right at its home, IIT Kharagpur on-campus healthcare system.

Director, Prof. V K Tewari stated, “In April we had announced eight R&D projects for providing COVID healthcare services. This telemedicine project is the key among them, especially, keeping in mind its effectiveness in our own community. When our campus will start operating in full strength close to 30000 people including students would be in need of healthcare services and this technology will reduce over-exposure of the healthcare staff while efficiently catering to the population. While we are promoting physical distancing, it seems only appropriate to introduce this digital platform to meet the healthcare needs of the campus community effectively. We are creating user accounts for our medical cardholders who can avail the consultation facility home through video conferencing”.

The software was launched on October 2, 2020, on the occasion of Gandhi Jayanti and will be integrated at the Dr B. C. Roy Technology Hospital of the Institute which provides emergency healthcare services for the campus residents and employees, confirmed the office of Principal Medical Officer Dr Samir Dasgupta.


Deputy Director, Prof. S K Bhattacharyya remarked, “Since we have a large number of OPD patients, it will be extremely beneficial to them as the movement to the hospital is extremely difficult for them. Also, for our students, the waiting time at the hospital will get reduced as this will be very helpful to them.”

A base model was installed at Swasthya Bhawan, Govt. of West Bengal on trial basis. Field trials are also underway for the base model at Bangladesh.

Director Tewari further shared his plan to expand the use of this technology to the people outside the campus through the upcoming super-speciality hospital of IIT Kharagpur.

The researchers are already in touch with healthcare MSMEs for commercialization of the copyrighted version of the technology.

Continue Reading

COVID19

COVID-19: 6Cr Indians Likely Exposed To Corona – 2nd ICMR Sero-Survey

Urban slum & non-slum areas have a higher prevalence of Corona infection than rural areas.

Published

on

NEW DELHI: ICMR’s second sero-survey findings released on Tuesday has revealed that one in 15 individuals aged 10 years and above were estimated to be exposed to SARS-CoV2 by August, showing that a considerable population is still susceptible to COVID-19.

Briefing media on Tuesday, DG ICMR Dr Balram Bhargava said, 6.6 per cent of over 29 thousand people, aged 10 and above, surveyed from 17th August to 22nd September showed evidence of past exposure to COVID-19 and 7.1 per cent of the adult population, aged 18 and above, also showed evidence of past exposure to it.

He said lockdown, containment and behavioural change at the population level have effectively checked the potential spread of SARS-CoV2.


Dr Bhargava said the risk in urban slums was twice than that in non-slum urban areas and four times the risk in rural settings.

He said that the second sero-survey was conducted in the same 700 villages and wards from 70 districts from 21 states which were covered during the first survey.

But this time, it surveyed different households and individuals.


The ICMR DG said, since a large proportion of the population is still susceptible, prevention fatigue has to be avoided and the 5T strategy — test, track, trace, treat, technology — has to be adhered to.

Continue Reading

Most Read This Month

error: Content on this news portal is protected!